| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 11214 | 2021 |
| Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes DJ Klionsky, H Abeliovich, P Agostinis, DK Agrawal, G Aliev, DS Askew, ... Autophagy 4 (2), 151-175, 2008 | 3256* | 2008 |
| Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells C Bellodi, MR Lidonnici, A Hamilton, GV Helgason, AR Soliera, ... The Journal of clinical investigation 119 (5), 1109-1123, 2009 | 706 | 2009 |
| Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells EM Kuntz, P Baquero, AM Michie, K Dunn, S Tardito, TL Holyoake, ... Nature medicine 23 (10), 1234-1240, 2017 | 511 | 2017 |
| Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival A Hamilton, GV Helgason, M Schemionek, B Zhang, S Myssina, EK Allan, ... Blood, The Journal of the American Society of Hematology 119 (6), 1501-1510, 2012 | 502 | 2012 |
| The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML D Vetrie, GV Helgason, M Copland Nature Reviews Cancer 20 (3), 158-173, 2020 | 297 | 2020 |
| Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/− knock-outs compared with wild-type mice M Bjarnadottir, DL Misner, S Haverfield-Gross, S Bruun, VG Helgason, ... Journal of Neuroscience 27 (17), 4519-4529, 2007 | 226 | 2007 |
| Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML GV Helgason, M Karvela, TL Holyoake Blood, The Journal of the American Society of Hematology 118 (8), 2035-2043, 2011 | 156 | 2011 |
| Targeting quiescent leukemic stem cells using second generation autophagy inhibitors P Baquero, A Dawson, A Mukhopadhyay, EM Kuntz, R Mitchell, ... Leukemia 33 (4), 981-994, 2019 | 130 | 2019 |
| Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia L de Beauchamp, E Himonas, GV Helgason Leukemia 36 (1), 1-12, 2022 | 109 | 2022 |
| ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells M Karvela, P Baquero, EM Kuntz, A Mukhopadhyay, R Mitchell, EK Allan, ... Autophagy 12 (6), 936-948, 2016 | 109 | 2016 |
| Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition R Mitchell, LEM Hopcroft, P Baquero, EK Allan, K Hewit, D James, ... JNCI: Journal of the National Cancer Institute 110 (5), 467-478, 2018 | 105 | 2018 |
| The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors F Pellicano, MT Scott, GV Helgason, LEM Hopcroft, EK Allan, ... Stem cells 32 (9), 2324-2337, 2014 | 100 | 2014 |
| Folate metabolism: a re-emerging therapeutic target in haematological cancers MM Zarou, A Vazquez, G Vignir Helgason Leukemia 35 (6), 1539-1551, 2021 | 88 | 2021 |
| Autophagy in blood cancers: biological role and therapeutic implications A Nencioni, M Cea, F Montecucco, VD Longo, F Patrone, AM Carella, ... haematologica 98 (9), 1335, 2013 | 73 | 2013 |
| Utilizing stimulated Raman scattering microscopy to study intracellular distribution of label-free ponatinib in live cells K Sepp, M Lee, MTJ Bluntzer, GV Helgason, AN Hulme, VG Brunton Journal of medicinal chemistry 63 (5), 2028-2034, 2019 | 68 | 2019 |
| A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease GA Horne, J Stobo, C Kelly, A Mukhopadhyay, AL Latif, J Dixon-Hughes, ... Leukemia 34 (7), 1775-1786, 2020 | 63 | 2020 |
| Role of autophagy in cancer prevention, development and therapy GV Helgason, TL Holyoake, KM Ryan Essays in biochemistry 55, 133-151, 2013 | 61 | 2013 |
| The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells F Pellicano, P Šimara, A Sinclair, GV Helgason, M Copland, S Grant, ... Leukemia 25 (7), 1159-1167, 2011 | 61 | 2011 |
| Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy G V. Helgason, A Mukhopadhyay, M Karvela, P Salomoni, B Calabretta, ... Current cancer drug targets 13 (7), 724-734, 2013 | 54 | 2013 |
Tessa L HolyoakeProfessor of Experimental Haematology, Institute of Cancer Sciences, University of Glasgowglasgow.ac.uk üzerinde doğrulanmış e-posta adresine sahip